G1 Therapeutics Inc [GTHX] stock prices are up 3.50% to $4.14 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The GTHX shares have gain 28.97% over the last week, with a monthly amount glided 86.49%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 1, March 2024, G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). In a post published today on Yahoo Finance, G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 2,100 shares of G1’s common stock and 1,050 restricted stock units (RSUs) to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Amended and Restated 2021 Plan”). These equity awards were granted as an inducement material to the new employee becoming an employee of G1 in accordance with Nasdaq Listing Rule 5635(c)(4).
From an analyst’s perspective:
G1 Therapeutics Inc [NASDAQ: GTHX] stock has seen the most recent analyst activity on January 30, 2023, when JP Morgan upgraded its rating to a Neutral and also boosted its price target to $10 from $7. Previously, Needham reaffirmed its Buy rating on January 03, 2023, and dropped its price target to $31. On November 04, 2021, downgrade downgraded it’s rating to Underweight and revised its price target to $19 on the stock. JP Morgan downgraded its rating to a Neutral and reduced its price target to $20 on September 30, 2021. Raymond James downgraded its rating to Outperform for this stock on November 17, 2020. In a note dated June 26, 2020, ROTH Capital initiated an Buy rating and provided a target price of $55 on this stock.
The stock price of G1 Therapeutics Inc [GTHX] has been fluctuating between $1.08 and $5.00 over the past year. G1 Therapeutics Inc [NASDAQ: GTHX] shares were valued at $4.14 at the most recent close of the market.
Analyzing the GTHX fundamentals
The G1 Therapeutics Inc [NASDAQ:GTHX] reported sales of 82.51M for trailing twelve months, representing a surge of 45.10%. Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at -0.48%, Pretax Profit Margin comes in at -0.54%, and Net Profit Margin reading is -0.64%. To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is 0.15 and Total Capital is -0.43. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.49.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.92 points at the first support level, and at 3.71 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.35, and for the 2nd resistance point, it is at 4.57.
G1 Therapeutics Inc [GTHX] reported earnings per share of -$0.21 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.27/share, meaning a difference of $0.06 and a surprise factor of 22.20%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.35 per share as compared to estimates of -$0.33 per share, a difference of -$0.02 representing a surprise of -6.10%.
Ratios To Look Out For
It’s worth pointing out that G1 Therapeutics Inc [NASDAQ:GTHX]’s Current Ratio is 3.87. On the other hand, the Quick Ratio is 3.45, and the Cash Ratio is 1.09. Considering the valuation of this stock, the price to sales ratio is 2.62, the price to book ratio is 6.08.
Transactions by insiders
Recent insider trading involved Umstead John W. V, Chief Financial Officer, that happened on Mar 18 ’24 when 6547.0 shares were sold. Chief Medical Officer, Malik Rajesh completed a deal on Feb 12 ’24 to sell 28600.0 shares. Meanwhile, Chief Operating Officer MURDOCK TERRY L sold 721.0 shares on Jan 04 ’24.
